Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Long-term studies for patients with resistant schizophrenia are necessary to assess the effectiveness of combination strategies on persisting positive symptoms. AIMS AND METHODS: This multicenter, naturalistic, randomized, superiority study (ClinicalTrials.gov identifier: NCT00395915) aimed to compare clinical efficacy and tolerability of haloperidol versus aripiprazole as combination treatment with clozapine in patients with resistant schizophrenia. RESULTS: One hundred six patients were followed up for 12 months. After 12 months, the proportion of patients who discontinued treatment was not significantly different between aripiprazole and haloperidol (37% vs 28%, respectively; P = 0.431). The change in the Brief Psychiatric Rating Scale score was similar in the aripiprazole and haloperidol groups (-7.0 vs -7.9, respectively; P = 0.389), whereas the tolerability total score decreased significantly more in the aripiprazole group (-7.2 vs -2.3; P = 0.008). CONCLUSIONS: While the effectiveness of clozapine augmentation with a second antipsychotic agent is not clearly demonstrated yet, results from this study suggest that augmentation with aripiprazole offers no substantial benefit over haloperidol in efficacy. Aripiprazole was perceived more tolerable than haloperidol, but it is uncertain how this finding may translate into the real world of clinical practice.

Original publication

DOI

10.1097/JCP.0b013e318296884f

Type

Journal article

Journal

J Clin Psychopharmacol

Publication Date

08/2013

Volume

33

Pages

533 - 537

Keywords

Antipsychotic Agents, Aripiprazole, Clozapine, Disease-Free Survival, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Italy, Kaplan-Meier Estimate, Linear Models, Multivariate Analysis, Piperazines, Proportional Hazards Models, Psychiatric Status Rating Scales, Quinolones, Schizophrenia, Schizophrenic Psychology, Time Factors, Treatment Outcome